FMCG Giant Procter & Gamble Health Recommends Rs 50/Share Dividend

Founded in 1837, Procter & Gamble Health is a large-cap FMCG American multinational consumer products firm with its global headquarters in Cincinnati, Ohio. Results for Q1FY24 have been released by the corporation, coupled with a massive dividend of Rs 50 per share.

"We are pleased to further inform you that the Board of Directors of the Company at its meeting held today, inter alia, have recommended a final dividend of Rs. 50 per equity share, for the financial year ended June 30, 2023. The dividend shall be paid between November 28, 2023 to December 18, 2023, on approval of the Members at the 56th Annual General Meeting," said Procter & Gamble Health in a stock exchange filing.

"The Board of Directors have recommended a final dividend of ₹ 50 per Equity Share, for the Financial Year ending June 30, 2023. Considering interim dividend of ₹ 45 per share, total dividend payout for the fiscal will be ₹ 95 per share, subject to the approval of final dividend by shareholders of the company at the ensuing 56th Annual General Meeting," said Procter & Gamble Health in its earning statement.

Procter & Gamble Health has announced an equity dividend of 525.00% at a face value of Rs 10 or Rs 52.5 per share for the fiscal year ending June 2022. This generates a dividend yield of 0.98% at the current share price of Rs 5120.60. The company has a solid track record of dividend declarations during the past five years. According to Trendlyne's statistics, Procter & Gamble Health Ltd. has issued 28 dividends since May 29, 2001.

Sales for the fourth quarter were recorded at Rs 306.6 crores, up nearly 3% from the same period last year. Due to increased material costs and one-time labour costs, the firm recorded a PAT of Rs 29.8 Crore, a 28% decrease from the prior year. For the fiscal year that ends on June 30, 2023, the firm reported outstanding growth with revenues of Rs. 1206 crores, up 10% over the prior year. Profit After Tax (PAT) increased 19% from the prior fiscal year to Rs 229 crores for the year that ended on June 30, 2023.

"We continued our efforts towards brand and category development and thus delivered a strong performance in the fiscal, marked by consistent growth across all our brands. The quarter, however, witnessed a category slowdown across our portfolio. Despite these challenges, we continued our commitment to our strategy of five integrated choices: a portfolio of daily-use products where performance drives brand choice; superiority across product, package, brand communication, retail execution, and value; productivity; constructive disruption of the entire value chain; and a highly efficient and effective organization structure," said Milind Thatte, Managing Director, Procter & Gamble Health Limited.

"We raised awareness and education among our consumers through initiatives like the Neuropathy Awareness Week, wherein leading Global Health Experts converged to address the growing Public Health Concern of Peripheral Neuropathy. This also reinforced our efforts towards building an ecosystem for scientific collaboration and knowledge-sharing among healthcare professionals," said Milind Thatte.

"We also commemorated World Health Day by launching the Pragati Utsav, an initiative to raise awareness and empower the healthcare professionals of rural hinterlands, on Vitamin B deficiency. We bolstered our go-to-market strategy and strengthened our partnerships across omni channel stores, increasing the availability and access of our brands across online and offline platforms, thereby helping meet the needs of our consumers and customers," said Milind Thatte.

"We launched the first-of-its-kind policies for employees, including the end-to-end support for children with special needs and a co pay India Day Care policy, we continued to foster an environment of equal opportunities at the workplace. SEHAT, our flagship CSR program, continued to remain a priority during this fiscal year where we continued to strengthen public health through our strategic initiatives," said Milind Thatte, Managing Director, Procter & Gamble Health Limited.